Personalizing health care: feasibility and future implications
Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated...
Ausführliche Beschreibung
Autor*in: |
Godman, Brian [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2013 |
---|
Schlagwörter: |
---|
Anmerkung: |
© Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
---|
Übergeordnetes Werk: |
Enthalten in: BMC medicine - London : BioMed Central, 2003, 11(2013), 1 vom: 13. Aug. |
---|---|
Übergeordnetes Werk: |
volume:11 ; year:2013 ; number:1 ; day:13 ; month:08 |
Links: |
---|
DOI / URN: |
10.1186/1741-7015-11-179 |
---|
Katalog-ID: |
SPR028351363 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR028351363 | ||
003 | DE-627 | ||
005 | 20230519191023.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2013 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/1741-7015-11-179 |2 doi | |
035 | |a (DE-627)SPR028351363 | ||
035 | |a (SPR)1741-7015-11-179-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Godman, Brian |e verfasserin |4 aut | |
245 | 1 | 0 | |a Personalizing health care: feasibility and future implications |
264 | 1 | |c 2013 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | ||
520 | |a Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. | ||
650 | 4 | |a Biomarkers |7 (dpeaa)DE-He213 | |
650 | 4 | |a Drug development |7 (dpeaa)DE-He213 | |
650 | 4 | |a Genomics |7 (dpeaa)DE-He213 | |
650 | 4 | |a Genotyping |7 (dpeaa)DE-He213 | |
650 | 4 | |a Healthcare policy |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pharmacogenetics precision medicine |7 (dpeaa)DE-He213 | |
650 | 4 | |a Personalized medicine |7 (dpeaa)DE-He213 | |
650 | 4 | |a Health authorities |7 (dpeaa)DE-He213 | |
650 | 4 | |a Rational use of medicines |7 (dpeaa)DE-He213 | |
650 | 4 | |a Reimbursement |7 (dpeaa)DE-He213 | |
650 | 4 | |a Targeted treatments |7 (dpeaa)DE-He213 | |
700 | 1 | |a Finlayson, Alexander E |4 aut | |
700 | 1 | |a Cheema, Parneet K |4 aut | |
700 | 1 | |a Zebedin-Brandl, Eva |4 aut | |
700 | 1 | |a Gutiérrez-Ibarluzea, Inaki |4 aut | |
700 | 1 | |a Jones, Jan |4 aut | |
700 | 1 | |a Malmström, Rickard E |4 aut | |
700 | 1 | |a Asola, Elina |4 aut | |
700 | 1 | |a Baumgärtel, Christoph |4 aut | |
700 | 1 | |a Bennie, Marion |4 aut | |
700 | 1 | |a Bishop, Iain |4 aut | |
700 | 1 | |a Bucsics, Anna |4 aut | |
700 | 1 | |a Campbell, Stephen |4 aut | |
700 | 1 | |a Diogene, Eduardo |4 aut | |
700 | 1 | |a Ferrario, Alessandra |4 aut | |
700 | 1 | |a Fürst, Jurij |4 aut | |
700 | 1 | |a Garuoliene, Kristina |4 aut | |
700 | 1 | |a Gomes, Miguel |4 aut | |
700 | 1 | |a Harris, Katharine |4 aut | |
700 | 1 | |a Haycox, Alan |4 aut | |
700 | 1 | |a Herholz, Harald |4 aut | |
700 | 1 | |a Hviding, Krystyna |4 aut | |
700 | 1 | |a Jan, Saira |4 aut | |
700 | 1 | |a Kalaba, Marija |4 aut | |
700 | 1 | |a Kvalheim, Christina |4 aut | |
700 | 1 | |a Laius, Ott |4 aut | |
700 | 1 | |a Lööv, Sven-Ake |4 aut | |
700 | 1 | |a Malinowska, Kamila |4 aut | |
700 | 1 | |a Martin, Andrew |4 aut | |
700 | 1 | |a McCullagh, Laura |4 aut | |
700 | 1 | |a Nilsson, Fredrik |4 aut | |
700 | 1 | |a Paterson, Ken |4 aut | |
700 | 1 | |a Schwabe, Ulrich |4 aut | |
700 | 1 | |a Selke, Gisbert |4 aut | |
700 | 1 | |a Sermet, Catherine |4 aut | |
700 | 1 | |a Simoens, Steven |4 aut | |
700 | 1 | |a Tomek, Dominik |4 aut | |
700 | 1 | |a Vlahovic-Palcevski, Vera |4 aut | |
700 | 1 | |a Voncina, Luka |4 aut | |
700 | 1 | |a Wladysiuk, Magdalena |4 aut | |
700 | 1 | |a van Woerkom, Menno |4 aut | |
700 | 1 | |a Wong-Rieger, Durhane |4 aut | |
700 | 1 | |a Zara, Corrine |4 aut | |
700 | 1 | |a Ali, Raghib |4 aut | |
700 | 1 | |a Gustafsson, Lars L |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC medicine |d London : BioMed Central, 2003 |g 11(2013), 1 vom: 13. Aug. |w (DE-627)377271225 |w (DE-600)2131669-7 |x 1741-7015 |7 nnns |
773 | 1 | 8 | |g volume:11 |g year:2013 |g number:1 |g day:13 |g month:08 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/1741-7015-11-179 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 11 |j 2013 |e 1 |b 13 |c 08 |
author_variant |
b g bg a e f ae aef p k c pk pkc e z b ezb i g i igi j j jj r e m re rem e a ea c b cb m b mb i b ib a b ab s c sc e d ed a f af j f jf k g kg m g mg k h kh a h ah h h hh k h kh s j sj m k mk c k ck o l ol s a l sal k m km a m am l m lm f n fn k p kp u s us g s gs c s cs s s ss d t dt v v p vvp l v lv m w mw w m v wm wmv d w r dwr c z cz r a ra l l g ll llg |
---|---|
matchkey_str |
article:17417015:2013----::esnlznhatcrfaiiiynf |
hierarchy_sort_str |
2013 |
publishDate |
2013 |
allfields |
10.1186/1741-7015-11-179 doi (DE-627)SPR028351363 (SPR)1741-7015-11-179-e DE-627 ger DE-627 rakwb eng Godman, Brian verfasserin aut Personalizing health care: feasibility and future implications 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. Biomarkers (dpeaa)DE-He213 Drug development (dpeaa)DE-He213 Genomics (dpeaa)DE-He213 Genotyping (dpeaa)DE-He213 Healthcare policy (dpeaa)DE-He213 Pharmacogenetics precision medicine (dpeaa)DE-He213 Personalized medicine (dpeaa)DE-He213 Health authorities (dpeaa)DE-He213 Rational use of medicines (dpeaa)DE-He213 Reimbursement (dpeaa)DE-He213 Targeted treatments (dpeaa)DE-He213 Finlayson, Alexander E aut Cheema, Parneet K aut Zebedin-Brandl, Eva aut Gutiérrez-Ibarluzea, Inaki aut Jones, Jan aut Malmström, Rickard E aut Asola, Elina aut Baumgärtel, Christoph aut Bennie, Marion aut Bishop, Iain aut Bucsics, Anna aut Campbell, Stephen aut Diogene, Eduardo aut Ferrario, Alessandra aut Fürst, Jurij aut Garuoliene, Kristina aut Gomes, Miguel aut Harris, Katharine aut Haycox, Alan aut Herholz, Harald aut Hviding, Krystyna aut Jan, Saira aut Kalaba, Marija aut Kvalheim, Christina aut Laius, Ott aut Lööv, Sven-Ake aut Malinowska, Kamila aut Martin, Andrew aut McCullagh, Laura aut Nilsson, Fredrik aut Paterson, Ken aut Schwabe, Ulrich aut Selke, Gisbert aut Sermet, Catherine aut Simoens, Steven aut Tomek, Dominik aut Vlahovic-Palcevski, Vera aut Voncina, Luka aut Wladysiuk, Magdalena aut van Woerkom, Menno aut Wong-Rieger, Durhane aut Zara, Corrine aut Ali, Raghib aut Gustafsson, Lars L aut Enthalten in BMC medicine London : BioMed Central, 2003 11(2013), 1 vom: 13. Aug. (DE-627)377271225 (DE-600)2131669-7 1741-7015 nnns volume:11 year:2013 number:1 day:13 month:08 https://dx.doi.org/10.1186/1741-7015-11-179 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2013 1 13 08 |
spelling |
10.1186/1741-7015-11-179 doi (DE-627)SPR028351363 (SPR)1741-7015-11-179-e DE-627 ger DE-627 rakwb eng Godman, Brian verfasserin aut Personalizing health care: feasibility and future implications 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. Biomarkers (dpeaa)DE-He213 Drug development (dpeaa)DE-He213 Genomics (dpeaa)DE-He213 Genotyping (dpeaa)DE-He213 Healthcare policy (dpeaa)DE-He213 Pharmacogenetics precision medicine (dpeaa)DE-He213 Personalized medicine (dpeaa)DE-He213 Health authorities (dpeaa)DE-He213 Rational use of medicines (dpeaa)DE-He213 Reimbursement (dpeaa)DE-He213 Targeted treatments (dpeaa)DE-He213 Finlayson, Alexander E aut Cheema, Parneet K aut Zebedin-Brandl, Eva aut Gutiérrez-Ibarluzea, Inaki aut Jones, Jan aut Malmström, Rickard E aut Asola, Elina aut Baumgärtel, Christoph aut Bennie, Marion aut Bishop, Iain aut Bucsics, Anna aut Campbell, Stephen aut Diogene, Eduardo aut Ferrario, Alessandra aut Fürst, Jurij aut Garuoliene, Kristina aut Gomes, Miguel aut Harris, Katharine aut Haycox, Alan aut Herholz, Harald aut Hviding, Krystyna aut Jan, Saira aut Kalaba, Marija aut Kvalheim, Christina aut Laius, Ott aut Lööv, Sven-Ake aut Malinowska, Kamila aut Martin, Andrew aut McCullagh, Laura aut Nilsson, Fredrik aut Paterson, Ken aut Schwabe, Ulrich aut Selke, Gisbert aut Sermet, Catherine aut Simoens, Steven aut Tomek, Dominik aut Vlahovic-Palcevski, Vera aut Voncina, Luka aut Wladysiuk, Magdalena aut van Woerkom, Menno aut Wong-Rieger, Durhane aut Zara, Corrine aut Ali, Raghib aut Gustafsson, Lars L aut Enthalten in BMC medicine London : BioMed Central, 2003 11(2013), 1 vom: 13. Aug. (DE-627)377271225 (DE-600)2131669-7 1741-7015 nnns volume:11 year:2013 number:1 day:13 month:08 https://dx.doi.org/10.1186/1741-7015-11-179 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2013 1 13 08 |
allfields_unstemmed |
10.1186/1741-7015-11-179 doi (DE-627)SPR028351363 (SPR)1741-7015-11-179-e DE-627 ger DE-627 rakwb eng Godman, Brian verfasserin aut Personalizing health care: feasibility and future implications 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. Biomarkers (dpeaa)DE-He213 Drug development (dpeaa)DE-He213 Genomics (dpeaa)DE-He213 Genotyping (dpeaa)DE-He213 Healthcare policy (dpeaa)DE-He213 Pharmacogenetics precision medicine (dpeaa)DE-He213 Personalized medicine (dpeaa)DE-He213 Health authorities (dpeaa)DE-He213 Rational use of medicines (dpeaa)DE-He213 Reimbursement (dpeaa)DE-He213 Targeted treatments (dpeaa)DE-He213 Finlayson, Alexander E aut Cheema, Parneet K aut Zebedin-Brandl, Eva aut Gutiérrez-Ibarluzea, Inaki aut Jones, Jan aut Malmström, Rickard E aut Asola, Elina aut Baumgärtel, Christoph aut Bennie, Marion aut Bishop, Iain aut Bucsics, Anna aut Campbell, Stephen aut Diogene, Eduardo aut Ferrario, Alessandra aut Fürst, Jurij aut Garuoliene, Kristina aut Gomes, Miguel aut Harris, Katharine aut Haycox, Alan aut Herholz, Harald aut Hviding, Krystyna aut Jan, Saira aut Kalaba, Marija aut Kvalheim, Christina aut Laius, Ott aut Lööv, Sven-Ake aut Malinowska, Kamila aut Martin, Andrew aut McCullagh, Laura aut Nilsson, Fredrik aut Paterson, Ken aut Schwabe, Ulrich aut Selke, Gisbert aut Sermet, Catherine aut Simoens, Steven aut Tomek, Dominik aut Vlahovic-Palcevski, Vera aut Voncina, Luka aut Wladysiuk, Magdalena aut van Woerkom, Menno aut Wong-Rieger, Durhane aut Zara, Corrine aut Ali, Raghib aut Gustafsson, Lars L aut Enthalten in BMC medicine London : BioMed Central, 2003 11(2013), 1 vom: 13. Aug. (DE-627)377271225 (DE-600)2131669-7 1741-7015 nnns volume:11 year:2013 number:1 day:13 month:08 https://dx.doi.org/10.1186/1741-7015-11-179 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2013 1 13 08 |
allfieldsGer |
10.1186/1741-7015-11-179 doi (DE-627)SPR028351363 (SPR)1741-7015-11-179-e DE-627 ger DE-627 rakwb eng Godman, Brian verfasserin aut Personalizing health care: feasibility and future implications 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. Biomarkers (dpeaa)DE-He213 Drug development (dpeaa)DE-He213 Genomics (dpeaa)DE-He213 Genotyping (dpeaa)DE-He213 Healthcare policy (dpeaa)DE-He213 Pharmacogenetics precision medicine (dpeaa)DE-He213 Personalized medicine (dpeaa)DE-He213 Health authorities (dpeaa)DE-He213 Rational use of medicines (dpeaa)DE-He213 Reimbursement (dpeaa)DE-He213 Targeted treatments (dpeaa)DE-He213 Finlayson, Alexander E aut Cheema, Parneet K aut Zebedin-Brandl, Eva aut Gutiérrez-Ibarluzea, Inaki aut Jones, Jan aut Malmström, Rickard E aut Asola, Elina aut Baumgärtel, Christoph aut Bennie, Marion aut Bishop, Iain aut Bucsics, Anna aut Campbell, Stephen aut Diogene, Eduardo aut Ferrario, Alessandra aut Fürst, Jurij aut Garuoliene, Kristina aut Gomes, Miguel aut Harris, Katharine aut Haycox, Alan aut Herholz, Harald aut Hviding, Krystyna aut Jan, Saira aut Kalaba, Marija aut Kvalheim, Christina aut Laius, Ott aut Lööv, Sven-Ake aut Malinowska, Kamila aut Martin, Andrew aut McCullagh, Laura aut Nilsson, Fredrik aut Paterson, Ken aut Schwabe, Ulrich aut Selke, Gisbert aut Sermet, Catherine aut Simoens, Steven aut Tomek, Dominik aut Vlahovic-Palcevski, Vera aut Voncina, Luka aut Wladysiuk, Magdalena aut van Woerkom, Menno aut Wong-Rieger, Durhane aut Zara, Corrine aut Ali, Raghib aut Gustafsson, Lars L aut Enthalten in BMC medicine London : BioMed Central, 2003 11(2013), 1 vom: 13. Aug. (DE-627)377271225 (DE-600)2131669-7 1741-7015 nnns volume:11 year:2013 number:1 day:13 month:08 https://dx.doi.org/10.1186/1741-7015-11-179 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2013 1 13 08 |
allfieldsSound |
10.1186/1741-7015-11-179 doi (DE-627)SPR028351363 (SPR)1741-7015-11-179-e DE-627 ger DE-627 rakwb eng Godman, Brian verfasserin aut Personalizing health care: feasibility and future implications 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. Biomarkers (dpeaa)DE-He213 Drug development (dpeaa)DE-He213 Genomics (dpeaa)DE-He213 Genotyping (dpeaa)DE-He213 Healthcare policy (dpeaa)DE-He213 Pharmacogenetics precision medicine (dpeaa)DE-He213 Personalized medicine (dpeaa)DE-He213 Health authorities (dpeaa)DE-He213 Rational use of medicines (dpeaa)DE-He213 Reimbursement (dpeaa)DE-He213 Targeted treatments (dpeaa)DE-He213 Finlayson, Alexander E aut Cheema, Parneet K aut Zebedin-Brandl, Eva aut Gutiérrez-Ibarluzea, Inaki aut Jones, Jan aut Malmström, Rickard E aut Asola, Elina aut Baumgärtel, Christoph aut Bennie, Marion aut Bishop, Iain aut Bucsics, Anna aut Campbell, Stephen aut Diogene, Eduardo aut Ferrario, Alessandra aut Fürst, Jurij aut Garuoliene, Kristina aut Gomes, Miguel aut Harris, Katharine aut Haycox, Alan aut Herholz, Harald aut Hviding, Krystyna aut Jan, Saira aut Kalaba, Marija aut Kvalheim, Christina aut Laius, Ott aut Lööv, Sven-Ake aut Malinowska, Kamila aut Martin, Andrew aut McCullagh, Laura aut Nilsson, Fredrik aut Paterson, Ken aut Schwabe, Ulrich aut Selke, Gisbert aut Sermet, Catherine aut Simoens, Steven aut Tomek, Dominik aut Vlahovic-Palcevski, Vera aut Voncina, Luka aut Wladysiuk, Magdalena aut van Woerkom, Menno aut Wong-Rieger, Durhane aut Zara, Corrine aut Ali, Raghib aut Gustafsson, Lars L aut Enthalten in BMC medicine London : BioMed Central, 2003 11(2013), 1 vom: 13. Aug. (DE-627)377271225 (DE-600)2131669-7 1741-7015 nnns volume:11 year:2013 number:1 day:13 month:08 https://dx.doi.org/10.1186/1741-7015-11-179 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 11 2013 1 13 08 |
language |
English |
source |
Enthalten in BMC medicine 11(2013), 1 vom: 13. Aug. volume:11 year:2013 number:1 day:13 month:08 |
sourceStr |
Enthalten in BMC medicine 11(2013), 1 vom: 13. Aug. volume:11 year:2013 number:1 day:13 month:08 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Biomarkers Drug development Genomics Genotyping Healthcare policy Pharmacogenetics precision medicine Personalized medicine Health authorities Rational use of medicines Reimbursement Targeted treatments |
isfreeaccess_bool |
true |
container_title |
BMC medicine |
authorswithroles_txt_mv |
Godman, Brian @@aut@@ Finlayson, Alexander E @@aut@@ Cheema, Parneet K @@aut@@ Zebedin-Brandl, Eva @@aut@@ Gutiérrez-Ibarluzea, Inaki @@aut@@ Jones, Jan @@aut@@ Malmström, Rickard E @@aut@@ Asola, Elina @@aut@@ Baumgärtel, Christoph @@aut@@ Bennie, Marion @@aut@@ Bishop, Iain @@aut@@ Bucsics, Anna @@aut@@ Campbell, Stephen @@aut@@ Diogene, Eduardo @@aut@@ Ferrario, Alessandra @@aut@@ Fürst, Jurij @@aut@@ Garuoliene, Kristina @@aut@@ Gomes, Miguel @@aut@@ Harris, Katharine @@aut@@ Haycox, Alan @@aut@@ Herholz, Harald @@aut@@ Hviding, Krystyna @@aut@@ Jan, Saira @@aut@@ Kalaba, Marija @@aut@@ Kvalheim, Christina @@aut@@ Laius, Ott @@aut@@ Lööv, Sven-Ake @@aut@@ Malinowska, Kamila @@aut@@ Martin, Andrew @@aut@@ McCullagh, Laura @@aut@@ Nilsson, Fredrik @@aut@@ Paterson, Ken @@aut@@ Schwabe, Ulrich @@aut@@ Selke, Gisbert @@aut@@ Sermet, Catherine @@aut@@ Simoens, Steven @@aut@@ Tomek, Dominik @@aut@@ Vlahovic-Palcevski, Vera @@aut@@ Voncina, Luka @@aut@@ Wladysiuk, Magdalena @@aut@@ van Woerkom, Menno @@aut@@ Wong-Rieger, Durhane @@aut@@ Zara, Corrine @@aut@@ Ali, Raghib @@aut@@ Gustafsson, Lars L @@aut@@ |
publishDateDaySort_date |
2013-08-13T00:00:00Z |
hierarchy_top_id |
377271225 |
id |
SPR028351363 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR028351363</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519191023.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1741-7015-11-179</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR028351363</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)1741-7015-11-179-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Godman, Brian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Personalizing health care: feasibility and future implications</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomarkers</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genomics</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genotyping</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Healthcare policy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacogenetics precision medicine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Personalized medicine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health authorities</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rational use of medicines</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Reimbursement</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Targeted treatments</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Finlayson, Alexander E</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheema, Parneet K</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zebedin-Brandl, Eva</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gutiérrez-Ibarluzea, Inaki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jones, Jan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Malmström, Rickard E</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Asola, Elina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baumgärtel, Christoph</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bennie, Marion</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bishop, Iain</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bucsics, Anna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Campbell, Stephen</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Diogene, Eduardo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrario, Alessandra</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fürst, Jurij</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garuoliene, Kristina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gomes, Miguel</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harris, Katharine</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haycox, Alan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Herholz, Harald</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hviding, Krystyna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jan, Saira</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kalaba, Marija</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kvalheim, Christina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laius, Ott</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lööv, Sven-Ake</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Malinowska, Kamila</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martin, Andrew</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McCullagh, Laura</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nilsson, Fredrik</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paterson, Ken</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schwabe, Ulrich</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Selke, Gisbert</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sermet, Catherine</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Simoens, Steven</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tomek, Dominik</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vlahovic-Palcevski, Vera</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Voncina, Luka</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wladysiuk, Magdalena</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Woerkom, Menno</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wong-Rieger, Durhane</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zara, Corrine</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ali, Raghib</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gustafsson, Lars L</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC medicine</subfield><subfield code="d">London : BioMed Central, 2003</subfield><subfield code="g">11(2013), 1 vom: 13. Aug.</subfield><subfield code="w">(DE-627)377271225</subfield><subfield code="w">(DE-600)2131669-7</subfield><subfield code="x">1741-7015</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:1</subfield><subfield code="g">day:13</subfield><subfield code="g">month:08</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/1741-7015-11-179</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2013</subfield><subfield code="e">1</subfield><subfield code="b">13</subfield><subfield code="c">08</subfield></datafield></record></collection>
|
author |
Godman, Brian |
spellingShingle |
Godman, Brian misc Biomarkers misc Drug development misc Genomics misc Genotyping misc Healthcare policy misc Pharmacogenetics precision medicine misc Personalized medicine misc Health authorities misc Rational use of medicines misc Reimbursement misc Targeted treatments Personalizing health care: feasibility and future implications |
authorStr |
Godman, Brian |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)377271225 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1741-7015 |
topic_title |
Personalizing health care: feasibility and future implications Biomarkers (dpeaa)DE-He213 Drug development (dpeaa)DE-He213 Genomics (dpeaa)DE-He213 Genotyping (dpeaa)DE-He213 Healthcare policy (dpeaa)DE-He213 Pharmacogenetics precision medicine (dpeaa)DE-He213 Personalized medicine (dpeaa)DE-He213 Health authorities (dpeaa)DE-He213 Rational use of medicines (dpeaa)DE-He213 Reimbursement (dpeaa)DE-He213 Targeted treatments (dpeaa)DE-He213 |
topic |
misc Biomarkers misc Drug development misc Genomics misc Genotyping misc Healthcare policy misc Pharmacogenetics precision medicine misc Personalized medicine misc Health authorities misc Rational use of medicines misc Reimbursement misc Targeted treatments |
topic_unstemmed |
misc Biomarkers misc Drug development misc Genomics misc Genotyping misc Healthcare policy misc Pharmacogenetics precision medicine misc Personalized medicine misc Health authorities misc Rational use of medicines misc Reimbursement misc Targeted treatments |
topic_browse |
misc Biomarkers misc Drug development misc Genomics misc Genotyping misc Healthcare policy misc Pharmacogenetics precision medicine misc Personalized medicine misc Health authorities misc Rational use of medicines misc Reimbursement misc Targeted treatments |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
BMC medicine |
hierarchy_parent_id |
377271225 |
hierarchy_top_title |
BMC medicine |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)377271225 (DE-600)2131669-7 |
title |
Personalizing health care: feasibility and future implications |
ctrlnum |
(DE-627)SPR028351363 (SPR)1741-7015-11-179-e |
title_full |
Personalizing health care: feasibility and future implications |
author_sort |
Godman, Brian |
journal |
BMC medicine |
journalStr |
BMC medicine |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2013 |
contenttype_str_mv |
txt |
author_browse |
Godman, Brian Finlayson, Alexander E Cheema, Parneet K Zebedin-Brandl, Eva Gutiérrez-Ibarluzea, Inaki Jones, Jan Malmström, Rickard E Asola, Elina Baumgärtel, Christoph Bennie, Marion Bishop, Iain Bucsics, Anna Campbell, Stephen Diogene, Eduardo Ferrario, Alessandra Fürst, Jurij Garuoliene, Kristina Gomes, Miguel Harris, Katharine Haycox, Alan Herholz, Harald Hviding, Krystyna Jan, Saira Kalaba, Marija Kvalheim, Christina Laius, Ott Lööv, Sven-Ake Malinowska, Kamila Martin, Andrew McCullagh, Laura Nilsson, Fredrik Paterson, Ken Schwabe, Ulrich Selke, Gisbert Sermet, Catherine Simoens, Steven Tomek, Dominik Vlahovic-Palcevski, Vera Voncina, Luka Wladysiuk, Magdalena van Woerkom, Menno Wong-Rieger, Durhane Zara, Corrine Ali, Raghib Gustafsson, Lars L |
container_volume |
11 |
format_se |
Elektronische Aufsätze |
author-letter |
Godman, Brian |
doi_str_mv |
10.1186/1741-7015-11-179 |
title_sort |
personalizing health care: feasibility and future implications |
title_auth |
Personalizing health care: feasibility and future implications |
abstract |
Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. © Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
abstractGer |
Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. © Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
abstract_unstemmed |
Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients. © Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2031 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2061 GBV_ILN_2111 GBV_ILN_2113 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
1 |
title_short |
Personalizing health care: feasibility and future implications |
url |
https://dx.doi.org/10.1186/1741-7015-11-179 |
remote_bool |
true |
author2 |
Finlayson, Alexander E Cheema, Parneet K Zebedin-Brandl, Eva Gutiérrez-Ibarluzea, Inaki Jones, Jan Malmström, Rickard E Asola, Elina Baumgärtel, Christoph Bennie, Marion Bishop, Iain Bucsics, Anna Campbell, Stephen Diogene, Eduardo Ferrario, Alessandra Fürst, Jurij Garuoliene, Kristina Gomes, Miguel Harris, Katharine Haycox, Alan Herholz, Harald Hviding, Krystyna Jan, Saira Kalaba, Marija Kvalheim, Christina Laius, Ott Lööv, Sven-Ake Malinowska, Kamila Martin, Andrew McCullagh, Laura Nilsson, Fredrik Paterson, Ken Schwabe, Ulrich Selke, Gisbert Sermet, Catherine Simoens, Steven Tomek, Dominik Vlahovic-Palcevski, Vera Voncina, Luka Wladysiuk, Magdalena van Woerkom, Menno Wong-Rieger, Durhane Zara, Corrine Ali, Raghib Gustafsson, Lars L |
author2Str |
Finlayson, Alexander E Cheema, Parneet K Zebedin-Brandl, Eva Gutiérrez-Ibarluzea, Inaki Jones, Jan Malmström, Rickard E Asola, Elina Baumgärtel, Christoph Bennie, Marion Bishop, Iain Bucsics, Anna Campbell, Stephen Diogene, Eduardo Ferrario, Alessandra Fürst, Jurij Garuoliene, Kristina Gomes, Miguel Harris, Katharine Haycox, Alan Herholz, Harald Hviding, Krystyna Jan, Saira Kalaba, Marija Kvalheim, Christina Laius, Ott Lööv, Sven-Ake Malinowska, Kamila Martin, Andrew McCullagh, Laura Nilsson, Fredrik Paterson, Ken Schwabe, Ulrich Selke, Gisbert Sermet, Catherine Simoens, Steven Tomek, Dominik Vlahovic-Palcevski, Vera Voncina, Luka Wladysiuk, Magdalena van Woerkom, Menno Wong-Rieger, Durhane Zara, Corrine Ali, Raghib Gustafsson, Lars L |
ppnlink |
377271225 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/1741-7015-11-179 |
up_date |
2024-07-03T18:54:53.803Z |
_version_ |
1803585211655520256 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR028351363</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519191023.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1741-7015-11-179</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR028351363</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)1741-7015-11-179-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Godman, Brian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Personalizing health care: feasibility and future implications</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Godman et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomarkers</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genomics</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genotyping</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Healthcare policy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacogenetics precision medicine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Personalized medicine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Health authorities</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rational use of medicines</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Reimbursement</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Targeted treatments</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Finlayson, Alexander E</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheema, Parneet K</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zebedin-Brandl, Eva</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gutiérrez-Ibarluzea, Inaki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jones, Jan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Malmström, Rickard E</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Asola, Elina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baumgärtel, Christoph</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bennie, Marion</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bishop, Iain</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bucsics, Anna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Campbell, Stephen</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Diogene, Eduardo</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrario, Alessandra</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fürst, Jurij</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Garuoliene, Kristina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gomes, Miguel</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harris, Katharine</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haycox, Alan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Herholz, Harald</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hviding, Krystyna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jan, Saira</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kalaba, Marija</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kvalheim, Christina</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Laius, Ott</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lööv, Sven-Ake</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Malinowska, Kamila</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martin, Andrew</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McCullagh, Laura</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nilsson, Fredrik</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paterson, Ken</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schwabe, Ulrich</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Selke, Gisbert</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sermet, Catherine</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Simoens, Steven</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tomek, Dominik</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vlahovic-Palcevski, Vera</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Voncina, Luka</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wladysiuk, Magdalena</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Woerkom, Menno</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wong-Rieger, Durhane</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zara, Corrine</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ali, Raghib</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gustafsson, Lars L</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC medicine</subfield><subfield code="d">London : BioMed Central, 2003</subfield><subfield code="g">11(2013), 1 vom: 13. Aug.</subfield><subfield code="w">(DE-627)377271225</subfield><subfield code="w">(DE-600)2131669-7</subfield><subfield code="x">1741-7015</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:1</subfield><subfield code="g">day:13</subfield><subfield code="g">month:08</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/1741-7015-11-179</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2013</subfield><subfield code="e">1</subfield><subfield code="b">13</subfield><subfield code="c">08</subfield></datafield></record></collection>
|
score |
7.4007063 |